Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Receivables (2016 - 2025)

Dexcom (DXCM) has disclosed Receivables for 16 consecutive years, with $1.2 billion as the latest value for Q4 2025.

  • Quarterly Receivables rose 19.7% to $1.2 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.2 billion through Dec 2025, up 19.7% year-over-year, with the annual reading at $1.2 billion for FY2025, 19.7% up from the prior year.
  • Receivables for Q4 2025 was $1.2 billion at Dexcom, up from $1.1 billion in the prior quarter.
  • The five-year high for Receivables was $1.4 billion in Q2 2025, with the low at $455.6 million in Q1 2021.
  • Average Receivables over 5 years is $825.9 million, with a median of $777.2 million recorded in 2023.
  • The sharpest move saw Receivables surged 62.86% in 2021, then increased 4.91% in 2024.
  • Over 5 years, Receivables stood at $529.3 million in 2021, then skyrocketed by 37.84% to $729.6 million in 2022, then surged by 34.58% to $981.9 million in 2023, then rose by 4.91% to $1.0 billion in 2024, then rose by 19.7% to $1.2 billion in 2025.
  • According to Business Quant data, Receivables over the past three periods came in at $1.2 billion, $1.1 billion, and $1.4 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.